Evidence map›Paper›PMID 27021338›Full record

ArticleRheumatology international2016

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.

Caramaschi Paola, Festi Giuliana, Orsolini Giovanni, Caimmi Cristian, Biasi Domenico

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Caramaschi PaolaUnità di Reumatologia, AOUI, Policlinico G.B. Rossi, P.le Scuro, 37134, Verona, Italy. paola.caramaschi@ospedaleuniverona.it.
Festi GiulianaUnità di Pneumologia, Dipartimento di Medicina, AOUI, Verona, Italy.
Orsolini GiovanniUnità di Reumatologia, AOUI, Policlinico G.B. Rossi, P.le Scuro, 37134, Verona, Italy.
Caimmi CristianUnità di Reumatologia, AOUI, Policlinico G.B. Rossi, P.le Scuro, 37134, Verona, Italy.
Biasi DomenicoUnità di Reumatologia, AOUI, Policlinico G.B. Rossi, P.le Scuro, 37134, Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to report three patients affected by interstitial lung disease associated with positive anti-SS-A/Ro autoantibody who showed a dramatic improvement after immunosuppressive treatment. Medical charts were reviewed to obtain clinical data, laboratory parameters, lung function tests, high-resolution computed tomography results and response to immunosuppressive treatment. The three patients showed a clinical picture of a lung-dominant connective tissue disease characterized by a sudden onset with dyspnea, cough and subtle extrathoracic features together with positive anti-SS-A/Ro antibody and weak titer antinuclear antibodies. All three patients responded favorably to immunosuppressive therapy: Two cases were treated with a combination of corticosteroid and cyclophosphamide followed by mycophenolate mofetil; in the third patient, clinical benefit was obtained after rituximab was added to corticosteroid and immunosuppressant drug. In spite of an abrupt onset with significant lung function impairment, all three patients had a favorable clinical response to immunosuppressive therapy. This report may be useful in making therapeutic decisions in case of interstitial lung disease associated with anti-SS-A antibody.

Indexed as

Adrenal Cortex HormonesAged, 80 and overAntibodies, AntinuclearBiomarkersCyclophosphamideDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsLungLung Diseases, InterstitialMiddle AgedMycophenolic AcidRecovery of FunctionRemission InductionRituximabAdrenal Cortex HormonesAntibodies, AntinuclearBiomarkersCyclophosphamideImmunosuppressive AgentsMycophenolic AcidRituximabSS-A antibodiesAnti-SS-A/Ro autoantibodyImmunosuppressive treatmentInterstitial lung disease

Identifiers

PMID27021338
OpenAlexW2332175090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.